Tedizolid Receives Qualified Infectious Disease Product (QIDP) Designation From FDA

Tedizolid Receives Qualified Infectious Disease Product (QIDP) Designation
From FDA

FDA's Action Expedites Regulatory Review Process of the New Drug Application
(NDA)

SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and
development of innovative antibiotics for serious infections, announced today
that the U.S. Food and Drug Administration (FDA) has designated the company's
Phase 3 antibiotic candidate, tedizolid phosphate, as a Qualified Infectious
Disease Product (QIDP). Trius received the designation for its current Phase 3
program of tedizolid for acute bacterial skin and skin structure infections
(ABSSSI) as well as the planned Phase 3 program for
hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). In
addition, the designations were granted for both the intravenous and oral
dosage forms of tedizolid. The QIDP designation will enable Trius to benefit
from certain incentives for the development of new antibiotics, including
priority review and eligibility for fast-track status. The QIDP designation
was created by the Generating Antibiotic Incentives Now (GAIN) Act, which was
part of the FDA Safety and Innovation Act (FDASIA).

"The FDA's QIDP designation for tedizolid is further confirmation that the
GAIN Act is aimed at promoting more rapid antibiotic development, and we are
pleased to receive the designation for both the intravenous and oral dosage
forms of tedizolid," said Jeffrey Stein, Ph.D., President and Chief Executive
Officer at Trius. "The tedizolid clinical program reflects our commitment to
bring safe, effective and convenient therapies to people with serious
infections."

Tedizolid recently completed enrollment of its second ABSSSI Phase 3 trial,
designated ESTABLISH 2, which examined the efficacy and safety of a six-day
course of tedizolid administered once a day versus a 10-day course of
linezolid (Zyvox^®) administered twice a day in patients recruited across
sites in North and South America, Europe, Australia, New Zealand and South
Africa. For both tedizolid and linezolid, drug was initially administered as
an intravenous (IV) infusion with the option to switch to oral therapy. In
September of 2012, Trius presented detailed results of its ESTABLISH 1 trial,
which tested the oral dosage form of tedizolid. The ESTABLISH 1 trial achieved
all FDA and European Medicines Agency (EMA) primary and secondary efficacy
outcomes and demonstrated significantly lower safety and tolerability events
compared to linezolid.

At December 31, 2012, Trius estimates that it had cash, cash equivalents and
investments totaling $66.0 million. This amount is preliminary, unaudited,
subject to change upon completion of our year-end audit, and may differ from
what will be reflected in our audited financial statements as of and for the
year ended December 31, 2012. Additional information and disclosures would be
required for a more complete understanding of our financial position and
results of operations as of December 31, 2012.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery and development of innovative antibiotics for serious infections.
The Company's lead investigational drug, tedizolid phosphate, is a once daily,
IV and orally administered second generation oxazolidinone in Phase 3 clinical
development for the treatment of serious gram-positive infections, including
those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has
partnered with Bayer HealthCare for the development and commercialization of
tedizolid phosphate outside of the U.S., Canada and the European Union. In
addition to the Company's tedizolid phosphate clinical program, Trius has
initiated IND-enabling studies for its Gyrase-B development candidate with
potent activity against Gram-negative bacterial pathogens including multi-drug
resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The
Gyrase-B program is one of the two preclinical programs supported by federal
contracts. For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding the following: Trius'
ability to successfully complete its ongoing clinical trials and development
programs; gaining FDA approval for tedizolid; transitioning into
commercialization; and estimated 2012 financial results. Risks that contribute
to the uncertain nature of the forward-looking statements include: the
accuracy of Trius' estimates regarding expenses, future revenues and capital
requirements; the success and timing of Trius' preclinical studies and
clinical trials; regulatory developments in the United States and foreign
countries; changes in Trius' plans to develop and commercialize its product
candidates; Trius' ability to obtain additional financing; Trius' ability to
obtain and maintain intellectual property protection for its product
candidates; and the loss of key scientific or management personnel. These and
other risks and uncertainties are described more fully in Trius' most recently
filed SEC documents, including its Form 10-K, Forms 10-Q and other documents
filed with the United States Securities and Exchange Commission, including
those factors discussed under the caption "Risk Factors" in such filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Trius undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507